Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.023
Neutral
RSI(14)
51.235
Neutral
STOCH(KDJ)(9,3,3)
53.310
Neutral
ATR(14)
0.115
High Vlolatility
CCI(14)
7.594
Neutral
Williams %R
71.207
Sell
TRIX(12,20)
0.463
Sell
StochRSI(14)
0.000
Sell
Search
Pulmatrix Inc
PULMAdd to Watchlist
1.650USD
-0.120-6.78%
Close 07-24 16:00（ET）Quotes delayed by 15 min
6.03MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-6.78%
5 Days
-2.37%
1 Month
+0.61%
6 Months
-35.04%
Year to Date
-26.01%
1 Year
-70.64%
Key Figures
1.780Open
1.780High
14.87KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
0.41%Turnover Ratio
1.770Prev. Close
1.648Low
18.75KTurnover
LossP/E Static
2.28P/B
0.00%Div Yield TTM
-72.14%ROA
9.37052wk High
1.33Volume Ratio
-9.56MNet Profit
3.65MShares
-1.2392EPS TTM
1.95Beta
-92.48%ROE
1.16052wk Low
7.48%Amplitude
100.00%Gross Margin
6.03MMarket Cap
1.70Reward/Risk
4.67%Risk Rate
TradingKey Stock Score of Pulmatrix Inc
Currency: USD Updated: 2026-07-24Key Insights
Pulmatrix Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 213 out of 386 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Pulmatrix Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Pulmatrix Inc Highlights
StrengthsRisks
Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.
Fairly Valued
The company’s latest PE is -1.33, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 369.44K shares, increasing 2.03% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.70.
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
Pulmatrix Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
0
analysts
--
Current Rating
Target Price
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Insmed Inc
INSM
23
1
2
3
...
100
Indicators
Moving Average
Indicators
Value
Direction
MA5
1.698
Sell
MA10
1.665
Sell
MA20
1.697
Sell
MA50
1.508
Buy
MA100
1.549
Buy
MA200
2.581
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Pulmatrix Inc Info
Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.
Ticker SymbolPULM
CompanyPulmatrix Inc
CEOLudlum (Peter B)
Websitehttps://www.pulmatrix.com/
Shareholders
Related Instruments
+0.88%
+1.60%
+0.90%
+0.46%
-0.72%
+0.43%
+1.22%
+1.25%
-1.18%
-0.12%
+0.94%
+0.90%
+1.20%
-0.02%
+2.04%
0.00%
+0.63%
-0.69%
+2.59%
+0.89%Popular Instruments
52475.400
+575.400 (+1.11%)
28586.200
+435.800 (+1.55%)
7485.200
+77.100 (+1.04%)
15110.000
+162.000 (+1.08%)
65109.000
+890.000 (+1.39%)
6361.300
+96.800 (+1.54%)
82.517
-7.526 (-8.36%)
333.020
+11.360 (+3.53%)
206.840
-1.920 (-0.92%)
4094.280
+41.930 (+1.03%)
FAQs
What is the current price of Pulmatrix Inc (PULM)?
The current price of Pulmatrix Inc (PULM) is 1.65.
What is the symbol of Pulmatrix Inc?
The ticker symbol of Pulmatrix Inc is PULM.
What is the 52-week high of Pulmatrix Inc?
The 52-week high of Pulmatrix Inc is 9.37.
What is the 52-week low of Pulmatrix Inc?
The 52-week low of Pulmatrix Inc is 1.16.
What is the market capitalization of Pulmatrix Inc?
The market capitalization of Pulmatrix Inc is 6.03M.
What is the Earnings Per Share (EPS TTM) of Pulmatrix Inc (PULM)?
The Earnings Per Share (EPS TTM) of Pulmatrix Inc (PULM) is -1.41.